Á¤È£¿¬ ¸íÀÇ

°ñ´Ù°øÁõ Áø·áÀÇ ¿À·£ °æÇè

Á¤È£¿¬ ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿°æÈñ´ëÇб³º´¿ø ³»ºÐºñ³»°ú
  • Àü¹®ºÐ¾ß
    °ñ´Ù°øÁõ, °»³â±âÁúȯ, °©»ó¼±, ´ç´¢º´, ³»ºÐºñÁúȯ

°æÈñ´ë ÀǴ븦 Á¹¾÷ÇÑ µÚ µ¿´ëÇпø¿¡¼­ ¼®¡¤¹Ú»ç ÇÐÀ§¸¦ ÃëµæÇß´Ù. ÇöÀç °­µ¿°æÈñ´ëº´¿ø ³»ºÐºñ³»°ú ±³¼ö´Ù.
³»ºÐºñ´ë»ç¼¾ÅÍÀå, °æ¿µ°ü¸®½ÇÀå, ±âȹÁø·áºÎ¿øÀåÀ» °ÅÃÄ Áö³­ 2015³âºÎÅÍ ¿ÃÇØ 3¿ù±îÁö´Â º´¿øÀåÀ¸·Î ¿ªÀÓÇß´Ù. °ñ´Ù°øÁõ Áø´Ü ¹× Ä¡·áÁöħ Àú¼ú¿¡ Âü¿©Çß´Ù. Àü¹® ºÐ¾ß´Â °ñ´Ù°øÁõ°ú °©»ó¼±, ´ç´¢º´, ºÎ½Å, ³»ºÐºñÁúȯ µîÀÌ´Ù. ³»ºÐºñ Áúȯ Áß¿¡¼­µµ ƯÈ÷ °ñ´Ù°øÁõ¿¡ ¸¹Àº °æÇèÀÌ ÀÖ¾î ¿©·¯ ¹æ¼ÛÀ» ÅëÇØ ¼Ò°³µÈ ÀÇ»ç´Ù. ÁÖ¿ä Áø·á ºÐ¾ß´Â °ñ´Ù°øÁõ ÁúȯÀ̸ç, 1997~1998³â »÷¾ÈÅä´Ï¿À ´ëÇаú 2002~2004³â ÇÇÃ÷¹ö±× ´ëÇп¡¼­ °ñ´Ù°øÁõ°ú °ü·ÃÇÑ ¿¬±¸¸¦ ÁøÇàÇß´Ù. °ñ´Ù°øÁõ ¿¬±¸ ³í¹®Àº ¹°·ÐÀÌ°í »õ·Î¿î ¾àÁ¦ °³¹ß°ú ¿¬°üµÈ ÀÓ»ó½ÃÇè¿¡ ´Ù³â°£ÀÇ °æÇèÀ» ÃàÀûÇϰí ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • 1994~ 1996 °æÈñ´ëÇб³ ÀÇÇаú ¹Ú»ç
  • 1987~ 1989 °æÈñ´ëÇб³ ÀÇÇаú ¼®»ç
  • 1980~ 1986 °æÈñ´ëÇб³ ÀÇÇаú Çлç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °æÈñ´ëÇб³ ±³¼ö
  • 2018~ 2019 ´ëÇѰñ´ë»çÇÐȸ ÀÌ»çÀå
  • 2015~ 2018 °­µ¿°æÈñ´ëº´¿ø ÀǴ뺴¿øÀå
  • 2015~ 2017 ´ëÇѳ»ºÐºñÇÐȸ ´ë»ç¼º°ñÁúȯ¿¬±¸È¸ ȸÀå
  • 2007~ 2012 °­µ¿°æÈñ´ëº´¿ø Áß¾Ó½ÇÇè½ÇÀå
  • 2006~ 2011 °­µ¿°æÈñ´ëº´¿ø ³»ºÐºñ³»°ú °úÀå
  • 2002~ 2004 University of Pittsburgh, research associate
  • 2001~ 2006 ¼º±Õ°ü´ëÇб³ ºÎ±³¼ö
  • 2003~ 2006 Á¦ÀϺ´¿ø ³»ºÐºñ³»°ú
  • 1997~ 1998 University of Texas at San Antonio, Postdoctoral fellow

¼ö»ó³»¿ª

Awards List
  • ´ëÇѰñ´ë»çÇÐȸ Çмú»ó (2000)
  • ´ëÇѰñ´ë»çÇÐȸ ¿ì¼ö³í¹®»ó (2008)
  • ´ëÇѰñ´ë»çÇÐȸ ¿ì¼ö³í¹®»ó (2013)

ÇÐȸȰµ¿

Academic activities
  • 2015 ~ 2017´ëÇѳ»ºÐºñÇÐȸ ´ë»ç¼º°ñÁúȯ¿¬±¸È¸ ȸÀå
  • 2018 ~ 2019´ëÇѰñ´ë»çÇÐȸ ÀÌ»çÀå
  • 2022 ~ 2024´ëÇѰñ´ë»çÇÐȸ Áø·áÁöħ¼­ ÆíÂùÀ§¿øÀå
  • 2023 ~ 2024´ëÇÑÀÇÇÐȸ °ñ´Ù°øÁõ ÀÓ»óÁø·áÁöħÀ§¿øÈ¸ À§¿øÀå
°ñ´Ù°øÁõ ±Ç°í ¿ä¾àº»
´ëÇ¥¼­Àû

°ñ´Ù°øÁõ ±Ç°í ¿ä¾àº»

  • ÀúÀÚ(±Û)Á¤È£¿¬
  • ÃâÆÇ»çÀ̹®±â¾÷
  • ¹ßÇàÀÏ2024
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 7°Ç
Á¦ ¸ñ ±Ù°¨¼ÒÁõ
ÃâÆÇ»ç ±ºÀÚÃâÆÇ»ç ¹ßÇàÀÏ 2017
Á¦ ¸ñ °ñ´Ù°øÁõ
ÃâÆÇ»ç 2016 ¹ßÇàÀÏ ±ºÀÚÃâÆÇ»ç
Á¦ ¸ñ °ñ´Ù°øÁõ
ÃâÆÇ»ç 2013 ¹ßÇàÀÏ ±ºÀÚÃâÆÇ»ç
Á¦ ¸ñ ³»ºÐºñ´ë»çÇÐ
ÃâÆÇ»ç 2022 ¹ßÇàÀÏ ±ºÀÚÃâÆÇ»ç
Á¦ ¸ñ ³»ºÐºñ´ë»çÇÐ
ÃâÆÇ»ç 2011 ¹ßÇàÀÏ ±ºÀÚÃâÆÇ»ç
Á¦ ¸ñ °ñ´Ù°øÁõ Áø·áÁöħ 2024
ÃâÆÇ»ç 2024 ¹ßÇàÀÏ ´ëÇѰñ´ë»çÇÐȸ
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Position statement: postmenopausal osteoporosis treatment strategies in Korea
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö JBM
Á¦ ¸ñ Effect of bazedoxifene/vitamin D combination therapy on serum vitamin D levels and BTM in postmenopausal women with osteopenia
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö JBM
Á¦ ¸ñ Denosumab-induced hypocalcemia in a patient with hyperthyroidism
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Osteoporos Int
Á¦ ¸ñ Delayed diagnosis of pseudohypoparthyroidism type1a with rare hypothyroidism since childhood
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Oxford Med Case Rep
Á¦ ¸ñ Raloxifene/vitamin D combination therapy vs. Raloxifene monotherapy on serum 25OHD level among PMO or osteopenia
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö JBM
Á¦ ¸ñ Effect of AGE products on differentiation and function of osteoblasts and osteoclasts
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö JKMS
Á¦ ¸ñ Incidence of subsequent osteoporotic fractures after distal radius fractures and mortality of subsequent distal radius fractrues
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Osteoporos Int

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

°ñ´Ù°øÁõÀÇ Áø·á¿¡¼­ °¡Àå ÃÖ½ÅÀÇ Ä¡·á¸¦, ±×¸®°í Ç¥ÁØÈ­µÈ Ä¡·á¸¦ ³Î¸® ¾Ë¸®´Â °ÍÀÌ Áß¿äÇÏ´Ù´Â Á¡¿¡¼­ ÇÐȸ¿¡¼­ ÁÖ±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ® µÇ´Â Áø·áÁöħ¼­ÀÇ ¹ß°£¿¡ Áö¼ÓÀûÀ¸·Î Âü¿©ÇÔ

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

¸ðµç ȯÀÚ°¡ ¶È°°Áö ¾Ê±â ¶§¹®¿¡ °¡Àå ȯÀÚ¿¡°Ô ÀûÀýÇϰí ÇÊ¿äÇÑ Áø·á ³»¿ëÀÌ ¹«¾ùÀΰ¡¸¦ ã¾Æ³»°í ¶ÇÇÑ °¡Àå À̵æÀÌ µÇ´Â Ä¡·á¸¦ À§ÇØ ³ë·ÂÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¸¸¼ºÀûÀÎ ÁúȯÀ¸·Î Áõ»óÀÌ ¾øÁö¸¸ Ä¡¸íÀûÀÎ °á°ú¸¦ º¸ÀÏ ¼ö ÀÖ´Â Áúº´ÀÎ ¸¸Å­ Áö¼ÓÀûÀÎ °ü½É°ú ³ë·ÂÀÌ ÇÊ¿äÇÏ°í ³ë·ÂÇÑ ¸¸Å­ »óÀÀÇÏ´Â À̵æÀÌ ÀÖÀ» ¼ö ÀÖ´Ù´Â »ý°¢ÀÌ ÇÊ¿äÇÔ

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿°æÈñ´ëÇб³º´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-5800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀÇ·á¼­ºñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î ƯȭµÈ ÇùÁø ÀÇ·á
¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.

°­µ¿°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ µ¿³²·Î 892

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä